A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight ...

Doctor, doctor, give me the news, Hims & Hers Health (HIMS) has got bad case of the stock market blues. The San Francisco ...

A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...

As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper ...

BofA notes that Judge Mark Pittman last night ruled in favor of the Food and Drug Administration, denying the Outsourcing Facilities ...

Hims&Hers Health shares are down over 8% premarket Thursday after a federal judge ruled in favor of the FDA in the tirzepatide compounding case.

This month pharmacies will no longer be allowed to sell lower-cost compounded versions of the anti-obesity drug tirzepatide — ...

Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...

Hims & Hers Health ( HIMS -12.79%) stock took a tumble Thursday morning, falling 9.2% through 11:40 a.m. ET on some ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of ...

Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...

Citi says a Texas Northern Court ruled yesterday against the Outsourcing Facilities Association’s preliminary injunction against the FDA ...